COVID-19 Vaccine Comparison: Covishield vs Covaxin vs Sputnik

COVISHIELD vs COVAXIN vs SPUTNIK V

 

COVID-19 Vaccine Comparison is here. India’s three COVID-19 vaccines are compared in terms of their technology, efficacy in clinical trials, adverse events, efficacy against mutant strains, storage conditions, dosing frequency, and gap, and their approval. Here is the snapshot of the COVID-19 vaccine comparison.

COVID-19 Vaccine Comparison –

 
 

COVISHIELD

COVAXIN

SPUTNIK V 

Company name

Oxford-Astra Zeneca

Bharat Biotech

Gamaleya

Other names

Vaxzevria, AZD1222

BBV 152

Gam-COVID-Vac

Technology

Viral Vector method using a weakened version of a common cold virus (adenovirus) from chimpanzees (ChAdOx1)

Inactivated 

virus 

technology

Viral Vector method using adenovirus 26 (Ad26) and 5 (Ad5) as vectors for the expression of SARS-CoV-2 spike protein

Efficacy in Phase 3 clinical trial (after the second dose)

81.3%

81%

(interim results)

91.6%

(interim results)

The gap between the first and second dose

12-16 weeks

4-6 weeks

3 weeks

First and Second Dose

Similar first and second doses

Similar first and second doses

Different first and second doses

Storage conditions

2-8 o C

(6 months)

2-8 o C

2-8 o C (dry)

-18.5 o C (liquid)

Efficacy against mutant variants

Reduced efficacy (70%) against B.1.1.7 (UK) variant and B.1.617 (Indian) variant. 

Reduced efficacy but lab experiments show some efficacy against B. 1.1.7 (UK), B.1.617 (Indian) variant, and P2 (Brazil) variants 

Less effective against B.1.351 (South African) variant but lab experiments show some efficacy against UK variant, efficacy not known against Indian variant

Common adverse events

Pain at the site of injection, redness, itching, swelling, fatigue, chills, headache, nausea, joint pain, muscle ache and generally feeling unwell, fever, vomiting, flu-like symptoms

Pain at the injection site, redness, swelling, itching, fever, body aches, nausea, vomiting, headache, rash

Sore arm, tiredness and a mild fever, headache, fatigue

Other adverse events

Abdominal pain, enlarged lymph nodes, excess sweating, rash. Blood clots in combination with low platelets have been confirmed as a rare but serious adverse event. 

Only one serious adverse event of viral pneumonitis reported unrelated to the vaccine.

Deep vein thrombosis, hemorhhagic stroke, and hypertension reported in a small number of people in the trial were not related to the vaccine

Approval in  countries

101 countries

9 countries

68 countries recognized recognized

Recognized by WHO for International travel

Yes

No (will seek approval from WHO)

No (will seek approval from WHO)

 

Related posts

Medical Disclaimer – The content, articles, and blogs on this website and its affiliated social media pages or third-party links are for educational and informational purpose and is not intended to replace medical advice, diagnosis, or treatment. The users and visitors on the website should always seek the advice of a qualified physician or other health care provider regarding questions or queries related to their personal health or medical conditions or before starting using a supplement or medication or making changes in their diet or exercise or following any other advice from our website. We take no responsibility for any health issue or personal injury, death, disability, or any other harm due to the content on our website or advice or opinion expressed on our website. Disclosure – As an Amazon associate, the site earns a commission for purchases made through links on the posts.

Loading